Rafferty Asset Management
LYEL icon

Rafferty Asset Management’s Lyell Immunopharma LYEL Stock Holding History

Rafferty Asset Management’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-21,244
Closed -$625K – 1087
2023
Q3 		$625K Buy
21,244
+4,980
+31% +$236K ﹤0.01% 884
2023
Q2 		$1.03M Sell
16,264
-9,050
-36% -$501K 0.01% 810
2023
Q1 		$1.19M Sell
25,314
-3,754
-13% -$201K 0.01% 757
2022
Q4 		$2.02M Buy
29,068
+18,748
+182% +$1.86M 0.02% 576
2022
Q3 		$1.51M Buy
+10,320
New +$1.4M 0.02% 572

Other funds holding LYEL

MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
WA
WuXi AppTec Shanghai, China $19M AUM 20.22% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Rafferty Asset Management's LYEL Position: Q4 2023 in Review

Rafferty Asset Management sold out of Lyell Immunopharma (LYEL) in Q4 2023, closing a stake of 21,244 shares — an estimated $625K sold.

Rafferty Asset Management first reported a position in LYEL in Q3 2022 and held it in 5 quarters. The position peaked at $2.02M in Q4 2022. 118 funds tracked by Wall St. Rank hold LYEL as of Q4 2023.

  • Rafferty Asset Management reported no remaining Lyell Immunopharma position as of Q4 2023 after selling out during the quarter.
  • Rafferty Asset Management sold 21,244 Lyell Immunopharma shares in Q4 2023, an estimated $625K.
  • Rafferty Asset Management first reported a position in Lyell Immunopharma in Q3 2022 and held it in 5 quarters.
  • Rafferty Asset Management's Lyell Immunopharma position peaked at $2.02M in Q4 2022.
  • 118 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q4 2023.

Based on Rafferty Asset Management's 13F filing for Q4 2023, filed 13 Feb 2024.